Federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there,” United Therapeutics (UT) said Tuesday in papers filed in federal district court in Washington, D.C.
Nothing in
…
Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients. It told entities they will be subject to the same allocation procedures as other buyers.
The
…
Medicare Part B reimbursement for physician-administered drugs is projected to rise from $18.7 billion in 2020 to $21.7 billion this year, and then to more than double to $46.2 billion by 2030, the Medicare Board of Trustees reported to Congress
…
Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15, the U.S. Health Resources and Services Administration (HRSA) announced
…
340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when hospitals use contract pharmacies to dispense drugs to patients.
Merck’s 340B contract pharmacy limitations will come on the heels of Boehringer Ingelheim’s
…
Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.
A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA temporarily now
…
Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in
…
The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.
U.S. Health and Human Services (HHS) Secretary
…
The U.S. Health Resources and Service Administration (HRSA) early this month invited community health centers to “resubmit a new” 340B administrative dispute resolution (ADR) petition against drug companies that deny or restrict 340B drug discounts when contract pharmacies are involved,
…
Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for arguments on
…*Sign up for news summaries and alerts from 340B Report